BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33372675)

  • 1. Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.
    Callens C; Vaur D; Soubeyran I; Rouleau E; Just PA; Guillerm E; Golmard L; Goardon N; Sevenet N; Cabaret O; Harter P; Gonzalez-Martin A; Fujiwara K; Cecere SC; Colombo N; Marth C; Vergote I; Maenpaa J; Pujade-Lauraine E; Ray-Coquard I
    J Natl Cancer Inst; 2021 Jul; 113(7):917-923. PubMed ID: 33372675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations.
    Schouten PC; Schmidt S; Becker K; Thiele H; Nürnberg P; Richters L; Ernst C; Treilleux I; Medioni J; Heitz F; Pisano C; Garcia Y; Petru E; Hietanen S; Colombo N; Vergote I; Nagao S; Linn SC; Pujade-Lauraine E; Ray-Coquard I; Harter P; Hahnen E; Schmutzler RK
    JAMA Netw Open; 2024 Apr; 7(4):e245552. PubMed ID: 38592722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline and somatic testing for ovarian Cancer: An SGO clinical practice statement.
    Gressel GM; Frey MK; Norquist B; Senter L; Blank SV; Urban RR
    Gynecol Oncol; 2024 Feb; 181():170-178. PubMed ID: 38215513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
    Lorusso D; Mouret-Reynier MA; Harter P; Cropet C; Caballero C; Wolfrum-Ristau P; Satoh T; Vergote I; Parma G; Nøttrup TJ; Lebreton C; Fasching PA; Pisano C; Manso L; Bourgeois H; Runnebaum I; Zamagni C; Hardy-Bessard AC; Schnelzer A; Fabbro M; Schmalfeldt B; Berton D; Belau A; Lotz JP; Gropp-Meier M; Gladieff L; Lück HJ; Abadie-Lacourtoisie S; Pujade-Lauraine E; Ray-Coquard I
    Int J Gynecol Cancer; 2024 Apr; 34(4):550-558. PubMed ID: 38129136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should all advanced BRCA-mutated patients in response to first-line platinum-based chemotherapy receive PARPi + bevacizumab as maintenance therapy?
    Turinetto M; Ray-Coquard I; Gourley C
    ESMO Open; 2024 May; 9(5):102983. PubMed ID: 38663167
    [No Abstract]   [Full Text] [Related]  

  • 6. Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial.
    Callens C; Rodrigues M; Briaux A; Frouin E; Eeckhoutte A; Pujade-Lauraine E; Renault V; Stoppa-Lyonnet D; Bieche I; Bataillon G; Karayan-Tapon L; Rochelle T; Heitz F; Cecere SC; Pérez MJR; Grimm C; Nøttrup TJ; Colombo N; Vergote I; Yonemori K; Ray-Coquard I; Stern MH; Popova T
    Oncogene; 2023 Nov; 42(48):3556-3563. PubMed ID: 37945748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma.
    Christinat Y; Ho L; Clément S; Genestie C; Sehouli J; Cinieri S; Gonzalez Martin A; Denison U; Fujiwara K; Vergote I; Tognon G; Hietanen S; Ray-Coquard I; Pujade-Lauraine E; McKee TA
    JCO Precis Oncol; 2023 Jun; 7():e2200555. PubMed ID: 37364234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting the likelihood of a
    Morgan RD; Burghel GJ; Flaum N; Bulman M; Smith P; Clamp AR; Hasan J; Mitchell C; Salih Z; Woodward ER; Lalloo F; Shaw J; Desai S; Crosbie EJ; Edmondson RJ; Schlecht H; Wallace AJ; Jayson GC; Evans DGR
    J Clin Pathol; 2023 Oct; 76(10):684-689. PubMed ID: 35738887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial.
    Loverix L; Vergote I; Busschaert P; Vanderstichele A; Venken T; Boeckx B; Harter P; Brems H; Van Nieuwenhuysen E; Pignata S; Baert T; Gonzalez-Martin A; Han S; Marth C; Neven P; Colombo N; Berteloot P; Mäenpää J; Olbrecht S; Laga T; Sablon E; Ray-Coquard I; Pujade-Lauraine E; Lambrechts D; Van Gorp T
    Eur J Cancer; 2023 Jul; 188():131-139. PubMed ID: 37245441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep Learning for Detecting BRCA Mutations in High-Grade Ovarian Cancer Based on an Innovative Tumor Segmentation Method From Whole Slide Images.
    Bourgade R; Rabilloud N; Perennec T; Pécot T; Garrec C; Guédon AF; Delnatte C; Bézieau S; Lespagnol A; de Tayrac M; Henno S; Sagan C; Toquet C; Mosnier JF; Kammerer-Jacquet SF; Loussouarn D
    Mod Pathol; 2023 Nov; 36(11):100304. PubMed ID: 37580018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1/2 Pathogenic Variants Are Not Common in Merkel Cell Carcinoma: Comprehensive Molecular Study of 30 Cases and Meta-Analysis of the Literature.
    Gaubert A; Kervarrec T; Montaudié H; Burel-Vandenbos F; Cardot-Leccia N; Di Mauro I; Fabas T; Tallet A; Kubiniek V; Pedeutour F; Dadone-Montaudié B
    J Invest Dermatol; 2023 Jul; 143(7):1178-1186. PubMed ID: 36754117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer.
    Boidot R; Blum MGB; Wissler MP; Gottin C; Ruzicka J; Chevrier S; Delhomme TM; Audoux J; Jeanniard A; Just PA; Harter P; Pignata S; González-Martin A; Marth C; Mäenpää J; Colombo N; Vergote I; Fujiwara K; Duforet-Frebourg N; Bertrand D; Philippe N; Ray-Coquard I; Pujade-Lauraine E;
    Eur J Cancer; 2024 May; 202():113978. PubMed ID: 38471290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features of germline BRCA1/2 or ATM pathogenic variant positive pancreatic cancer in Japan.
    Kitamura H; Morizane C; Tanabe N; Go I; Maruki Y; Ohba A; Nagashio Y; Kondo S; Hijioka S; Ueno H; Yoshida T; Okusaka T
    Pancreatology; 2023 Dec; 23(8):964-969. PubMed ID: 37914629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives of Healthcare Professionals on the Management and Treatment of Advanced Ovarian Cancer in the UK: Results From the KNOW-OC Survey.
    Fotopoulou C; Hall M; Lord R; Miller R; Sundar S; Roebuck N; Fildes L; Wesselbaum A; McCormack S; Hickey J; Ledermann J
    Clin Oncol (R Coll Radiol); 2024 Jan; 36(1):e1-e10. PubMed ID: 37923688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
    Poveda A; Floquet A; Ledermann JA; Asher R; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Friedlander M; Baldoni A; Park-Simon TW; Tamura K; Sonke GS; Lisyanskaya A; Kim JH; Filho EA; Milenkova T; Lowe ES; Rowe P; Vergote I; Pujade-Lauraine E;
    Lancet Oncol; 2021 May; 22(5):620-631. PubMed ID: 33743851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial
    Wu XH; Zhu JQ; Yin RT; Yang JX; Liu JH; Wang J; Wu LY; Liu ZL; Gao YN; Wang DB; Lou G; Yang HY; Zhou Q; Kong BH; Huang Y; Chen LP; Li GL; An RF; Wang K; Zhang Y; Yan XJ; Lu X; Lu WG; Hao M; Wang L; Cui H; Chen QH; Abulizi G; Huang XH; Tian XF; Wen H; Zhang C; Hou JM; Mirza MR
    Ann Oncol; 2021 Apr; 32(4):512-521. PubMed ID: 33453391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
    Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
    Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibitors in ovarian cancer: An overview of the practice-changing trials.
    Foo T; George A; Banerjee S
    Genes Chromosomes Cancer; 2021 May; 60(5):385-397. PubMed ID: 33382149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.
    Friedlander M; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Lisyanskaya A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley WH; Liu J; Mathews C; Selle F; Lortholary A; Lowe ES; Hettle R; Flood E; Parkhomenko E; DiSilvestro P
    Lancet Oncol; 2021 May; 22(5):632-642. PubMed ID: 33862001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
    Armstrong DK; Alvarez RD; Bakkum-Gamez JN; Barroilhet L; Behbakht K; Berchuck A; Chen LM; Cristea M; DeRosa M; Eisenhauer EL; Gershenson DM; Gray HJ; Grisham R; Hakam A; Jain A; Karam A; Konecny GE; Leath CA; Liu J; Mahdi H; Martin L; Matei D; McHale M; McLean K; Miller DS; O'Malley DM; Percac-Lima S; Ratner E; Remmenga SW; Vargas R; Werner TL; Zsiros E; Burns JL; Engh AM
    J Natl Compr Canc Netw; 2021 Feb; 19(2):191-226. PubMed ID: 33545690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.